Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 76

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D)

Carrasco-Labra, Alonso, Lytvyn, Lyubov, Falck-Ytter, Yngve, Surawicz, Christina M., Chey, William D.·2019·Gastroenterology
DOI 10.1053/j.gastro.2019.06.014
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2019.06.014

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 80

  1. Spiegel, 2010, Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts, Am J Gastroenterol, 105, 848, 10.1038/ajg.2010.47 · DOI
  2. Ford, 2014, American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation, Am J Gastroenterol, 109, S2, 10.1038/ajg.2014.187 · DOI
  3. Weinberg, 2014, American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome, Gastroenterology, 147, 1146, 10.1053/j.gastro.2014.09.001 · DOI
  4. Spiegel, 2009, The burden of IBS: looking at metrics, Curr Gastroenterol Rep, 11, 265, 10.1007/s11894-009-0039-x · DOI
  5. Koloski, 2001, Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors, Am J Gastroenterol, 96, 1340, 10.1111/j.1572-0241.2001.03789.x · DOI · Paper page
  6. Everhart, 2009, Burden of digestive diseases in the United States part II: lower gastrointestinal diseases, Gastroenterology, 136, 741, 10.1053/j.gastro.2009.01.015 · DOI
  7. Agarwal, 2011, The effect of irritable bowel syndrome on health-related quality of life and health care expenditures, Gastroenterol Clin North Am, 40, 11, 10.1016/j.gtc.2010.12.013 · DOI
  8. Sood, 2015, Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers, Aliment Pharmacol Ther, 42, 491, 10.1111/apt.13283 · DOI
  9. Mearin, 2016, Bowel disorders, Gastroenterology
  10. Ford, 2008, Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis, Gut, 57, 1545, 10.1136/gut.2008.159723 · DOI · Paper page
  11. Ford, 2015, Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care, Am J Gastroenterol, 110, 716, 10.1038/ajg.2015.117 · DOI
  12. Simpkins, 2017, Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care, Aliment Pharmacol Ther, 45, 91, 10.1111/apt.13846 · DOI
  13. Loftus, 2016, Update on the incidence and prevalence of inflammatory bowel disease in the United States, Gastroenterol Hepatol (N Y), 12, 704
  14. Loftus, 2004, Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences, Gastroenterology, 126, 1504, 10.1053/j.gastro.2004.01.063 · DOI
  15. 2004, NIH Consensus Development Conference on Celiac Disease, NIH Consens State Sci Statements, 21, 1
  16. Fasano, 2003, Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study, Arch Intern Med, 163, 286, 10.1001/archinte.163.3.286 · DOI
  17. Bates, 2015, Fitting linear mixed-effects models using lme4, J Stat Softw, 67, 1
  18. Catassi, 2007, Detection of celiac disease in primary care: A multicenter case-finding study in North America, Am J Gastroenterol, 102, 1454, 10.1111/j.1572-0241.2007.01173.x · DOI
  19. Dickey, 1998, Identification of coeliac disease in primary care, Scand J Gastroenterol, 33, 491, 10.1080/00365529850172043 · DOI
  20. Kalantari, 2015, Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome, Advanced Biomedical Research, 4, 85, 10.4103/2277-9175.156647 · DOI
  21. Langenberg, 2014, Distinguishing tropical sprue from celiac disease in returning travellers with chronic diarrhoea: a diagnostic challenge?, Travel Med Infect Dis, 12, 401, 10.1016/j.tmaid.2014.05.001 · DOI
  22. Otten, 2008, Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. [Erratum appears in Clin Chem Lab Med. 2008;46(12):1798], Clin Chem Lab Med, 46, 1275
  23. Yagil, 2005, Serologic testing for celiac disease in young adults—a cost-effect analysis, Dig Dis Sci, 50, 796, 10.1007/s10620-005-2576-y · DOI
  24. Caccaro, 2014, Fecal lactoferrin and intestinal permeability are effective non-invasive markers in the diagnostic work-up of chronic diarrhea, BioMetals, 27, 1069, 10.1007/s10534-014-9745-4 · DOI
  25. Carroccio, 2003, Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children, Clin Chem, 49, 861, 10.1373/49.6.861 · DOI
  26. Carroccio, 2002, Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study, Clinical Chemistry, 48, 1546, 10.1093/clinchem/48.9.1546 · DOI
  27. Cash, 2011, The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls, Gastroenterology, 141, 1187, 10.1053/j.gastro.2011.06.084 · DOI
  28. Caviglia, 2014, Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders, Scand J Gastroenterol, 49, 1419, 10.3109/00365521.2014.934913 · DOI
  29. Costa, 2003, Role of faecal calprotectin as non-invasive marker of intestinal inflammation, Digest Liver Dis, 35, 642, 10.1016/S1590-8658(03)00381-5 · DOI · Paper page
  30. Dickey, 1997, Association between serum levels of total IgA and IgA class endomysial and antigliadin antibodies: implications for coeliac disease screening, Eur J Gastroenterol Hepatol, 9, 559, 10.1097/00042737-199706000-00002 · DOI
  31. Dolwani, 2004, Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology, Aliment Pharmacol Ther, 20, 615, 10.1111/j.1365-2036.2004.02128.x · DOI
  32. Hadithi, 2007, Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease, Ann Intern Med, 147, 294, 10.7326/0003-4819-147-5-200709040-00003 · DOI
  33. Hopper, 2007, Pre-endoscopy serological testing for coeliac disease: evaluation of a clinical decision tool, Bmj, 334, 729, 10.1136/bmj.39133.668681.BE · DOI
  34. Kaiser, 2007, Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome, Gut, 56, 1706, 10.1136/gut.2006.113431 · DOI
  35. Kane, 2003, Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation, Am J Gastroenterol, 98, 1309, 10.1111/j.1572-0241.2003.07458.x · DOI · Paper page
  36. Langhorst, 2008, Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices, Am J Gastroenterol, 103, 162, 10.1111/j.1572-0241.2007.01556.x · DOI · Paper page
  37. Poullis, 2002, A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders, Eur J Gastroenterol Hepatol, 14, 409, 10.1097/00042737-200204000-00013 · DOI
  38. Rashtak, 2008, Combination testing for antibodies in the diagnosis of coeliac disease: comparison of multiplex immunoassay and ELISA methods, Aliment Pharmacol Ther, 28, 805, 10.1111/j.1365-2036.2008.03797.x · DOI
  39. Schoepfer, 2008, Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies, Inflamm Bowel Dis, 14, 32, 10.1002/ibd.20275 · DOI · Paper page
  40. Schroder, 2007, Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin, Aliment Pharmacol Ther, 26, 1035, 10.1111/j.1365-2036.2007.03457.x · DOI
  41. Shahbazkhani, 2003, Coeliac disease presenting with symptoms of irritable bowel syndrome, Aliment Pharmacol Ther, 18, 231, 10.1046/j.1365-2036.2003.01666.x · DOI
  42. Shine, 1985, C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders, Clin Chim Acta, 148, 105, 10.1016/0009-8981(85)90219-0 · DOI
  43. Sidhu, 2010, Faecal lactoferrin—a novel test to differentiate between the irritable and inflamed bowel?, Aliment Pharmacol Ther, 31, 1365, 10.1111/j.1365-2036.2010.04306.x · DOI
  44. Tesei, 2003, Antibodies to human recombinant tissue transglutaminase may detect coeliac disease patients undiagnosed by endomysial antibodies, Aliment Pharmacol Ther, 17, 1415, 10.1046/j.1365-2036.2003.01595.x · DOI
  45. Tibble, 2000, A simple method for assessing intestinal inflammation in Crohn's disease, Gut, 47, 506, 10.1136/gut.47.4.506 · DOI
  46. Valdimarsson, 1996, Is small bowel biopsy necessary in adults with suspected celiac disease and IgA anti-endomysium antibodies? 100% positive predictive value for celiac disease in adults, Dig Dis Sci, 41, 83, 10.1007/BF02208588 · DOI
  47. Wahnschaffe, 2007, Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome, Clin Gastroenterol Hepatol, 5, 844, 10.1016/j.cgh.2007.03.021 · DOI
  48. Wassell, 2004, Faecal calprotectin: a new marker for Crohn's disease?, Ann Clin Biochem, 41, 230, 10.1258/000456304323019613 · DOI
  49. Chang, 2014, Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome, Mol Med Rep, 10, 522, 10.3892/mmr.2014.2180 · DOI
  50. Merrick, 1985, Is bile acid malabsorption underdiagnosed? An evaluation of accuracy of diagnosis by measurement of SeHCAT retention, Br Med J (Clin Res Ed), 290, 665, 10.1136/bmj.290.6469.665 · DOI
  51. Oikonomou, 2012, Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity, J Gastroenterol, 47, 519, 10.1007/s00535-011-0516-5 · DOI
  52. Sciarretta, 1986, Use of 23-selena-25-homocholyltaurine to detect bile acid malabsorption in patients with illeal dysfunction or diarrhea, Gastroenterology, 91, 1, 10.1016/0016-5085(86)90431-2 · DOI
  53. Sciarretta, 1987, 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit, Gut, 28, 970, 10.1136/gut.28.8.970 · DOI
  54. Schmulson, 2016, Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico, Rev Gastroenterol Mexico, 81, 236
  55. Valentin, 2016, Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis, Gut, 65, 1951, 10.1136/gutjnl-2015-309889 · DOI
  56. Soares, 2016, Giardiasis: an update review on sensitivity and specificity of methods for laboratorial diagnosis, J Microbiol Methods, 129, 98, 10.1016/j.mimet.2016.08.017 · DOI
  57. McHardy, 2014, Detection of intestinal protozoa in the clinical laboratory, J Clin Microbiol, 52, 712, 10.1128/JCM.02877-13 · DOI
  58. Kappelman, 2007, The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States, Clin Gastroenterol Hepatol, 5, 1424, 10.1016/j.cgh.2007.07.012 · DOI · Paper page
  59. Menees, 2015, A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS, Am J Gastroenterol, 110, 444, 10.1038/ajg.2015.6 · DOI · Paper page
  60. Bibbins-Domingo, 2017, Screening for celiac disease: US Preventive Services Task Force Recommendation Statement, JAMA, 317, 1252, 10.1001/jama.2017.1462 · DOI
  61. Dube, 2005, The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review, Gastroenterology, 128, S57, 10.1053/j.gastro.2005.02.014 · DOI
  62. Rubio-Tapia, 2009, Increased prevalence and mortality in undiagnosed celiac disease, Gastroenterology, 137, 88, 10.1053/j.gastro.2009.03.059 · DOI · Paper page
  63. West, 2004, Malignancy and mortality in people with coeliac disease: population based cohort study, Bmj, 329, 716, 10.1136/bmj.38169.486701.7C · DOI · Paper page
  64. Rubio-Tapia, 2013, ACG clinical guidelines: diagnosis and management of celiac disease, Am J Gastroenterol, 108, 656, 10.1038/ajg.2013.79 · DOI
  65. Bai, 2013, World Gastroenterology Organisation global guidelines on celiac disease, J Clin Gastroenterol, 47, 121, 10.1097/MCG.0b013e31827a6f83 · DOI
  66. Hill, 2016, NASPGHAN Clinical Report on the Diagnosis and Treatment of Gluten-Related Disorders, J Pediatr Gastroenterol Nutr, 63, 156, 10.1097/MPG.0000000000001216 · DOI
  67. McGowan, 2008, Celiac disease and IgA deficiency: complications of serological testing approaches encountered in the clinic, Clin Chem, 54, 1203, 10.1373/clinchem.2008.103606 · DOI
  68. Vijayvargiya, 2013, Methods for diagnosis of bile acid malabsorption in clinical practice, Clin Gastroenterol Hepatol, 11, 1232, 10.1016/j.cgh.2013.04.029 · DOI
  69. Mottacki, 2016, Review article: bile acid diarrhoea—pathogenesis, diagnosis and management, Aliment Pharmacol Ther, 43, 884, 10.1111/apt.13570 · DOI
  70. Pattni, 2012, Fibroblast growth factor 19 and 7alpha-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea, Clin Transl Gastroenterol, 3, e18, 10.1038/ctg.2012.10 · DOI
  71. Mosli, 2012, Nonutility of routine testing of stool for ova and parasites in a tertiary care Canadian centre, Can J Microbiol, 58, 653, 10.1139/w2012-039 · DOI
  72. Perry, 2017, Evaluation of the BD MAX Enteric Parasite Panel for the detection of Cryptosporidium parvum/hominis, Giardia duodenalis and Entamoeba histolytica, J Med Microbiol, 66, 1118, 10.1099/jmm.0.000558 · DOI
  73. Pimentel, 2008, A new rat model links two contemporary theories in irritable bowel syndrome, Dig Dis Sci, 53, 982, 10.1007/s10620-007-9977-z · DOI
  74. Pardi, 2017, Diagnosis and management of microscopic colitis, Am J Gastroenterol, 112, 78, 10.1038/ajg.2016.477 · DOI
  75. Genta, 2015, The yield of colonic biopsy in the evaluation of chronic unexplained diarrhea, Eur J Gastroenterol Hepatol, 27, 963, 10.1097/MEG.0000000000000365 · DOI
  76. Kamp, 2016, Irritable bowel syndrome and microscopic colitis: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 14, 659, 10.1016/j.cgh.2015.09.031 · DOI
  77. Hilmi, 2013, Low prevalence of ‘classical' microscopic colitis but evidence of microscopic inflammation in Asian irritable bowel syndrome patients with diarrhoea, BMC Gastroenterol, 13, 80, 10.1186/1471-230X-13-80 · DOI
  78. Ozdil, 2011, The frequency of microscopic and focal active colitis in patients with irritable bowel syndrome, BMC Gastroenterol, 11, 96, 10.1186/1471-230X-11-96 · DOI
  79. Tuncer, 2003, Prevalence of microscopic colitis in patients with symptoms suggesting irritable bowel syndrome, Acta Gastroenterol Belg, 66, 133
  80. Cantarini, 2012, Ileocolorectal inflammation and psychopathological status in patients with diarrhea-predominant functional bowel disorders, Neurogastroenterol Motil, 24, 103

Cited by

See all 76

Metadata

Authors
Carrasco-Labra, A., Lytvyn, L., Falck-Ytter, Y., Surawicz, C. M., & Chey, W. D.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2019-09
Volume
157
Issue
3
Pages
859-880
ISSN
0016-5085
DOI
10.1053/j.gastro.2019.06.014
Cited by
76
References
7
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Working Dog Centre, Massey University
  • Administration for Community Living (CMS)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.